(Reuters) -AstraZeneca is in talks with Summit Therapeutics to license an experimental lung-cancer drug under a deal worth as much as $15 billion, Bloomberg News reported on Thursday, citing people ...
Shares of clinical-stage company Summit Therapeutics SMMT rose nearly 9% on Thursday following a report issued by Bloomberg, which stated that pharma giant AstraZeneca AZN is in discussions with the ...
Summit Therapeutics Inc. (NASDAQ:SMMT) is one of the 10 Stocks Going Wild. Summit Therapeutics jumped by 7.61 percent on Wednesday, a second day, to close at $24.74 apiece as reports about a ...
AstraZeneca PLC (NASDAQ:AZN) is one of the best high growth stocks. Bloomberg reported on July 3 that AstraZeneca is engaged in negotiations with Summit Therapeutics Inc. (NASDAQ:SMMT) regarding a ...
DelveInsight's EGFR Inhibitors Market Size, Target Population, Competitive Landscape & Market Forecast report includes a ...
The media outlet in question was Bloomberg, which that morning published an article asserting that AstraZeneca is in talks with Summit about a partnership between the two companies. According to ...
Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox. Morning! Today, we’ll get caught up with highlights from the annual meeting ...
SMMT surged after reports of AstraZeneca exploring a $15 billion licensing deal for ivonescimab. The deal may include billions upfront, with milestone payments tied to Ivonescimab's progress.
The outlook for the EGFR inhibitor market continues to be highly promising, supported by the increasing adoption of precision medicine in oncology and the broader use of targeted therapies across ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results